Figure 9.
Structures of multimodal MAO-B and adenosine 2A receptor antagonists developed as anti-Parkinson drugs from caffeine.
Figure 9.
Structures of multimodal MAO-B and adenosine 2A receptor antagonists developed as anti-Parkinson drugs from caffeine.